Vaxcyte said its next-generation pneumococcal vaccine, VAX-31, met key endpoints in a Phase 3 trial in adults, triggering a sharp stock reaction. The candidate is designed to cover 31 pneumococcal serotypes, and the company framed results as competitive against established vaccines from Pfizer and Merck.